Author: WTN News

Information technology executives from around the world received some futristic advice during Gartner Symposium/ITxpo 2007 - specifically that in these days of economic uncertainty, it's time to take IT to the next level. Step one is for CIOs to view themselves as business leaders, rather...

A confluence of factors have merged to require CIOs to view themselves not as technology leaders but business leaders. The opportunities to do so, which include having an impact when the economy is showing signs of slowing down, was a major theme of Gartner Symposium/ITxpo...

Columnist Michael Rosen does some Bio-MidAmerican Investor Conference follow up and looks at a recent report ranking the climate for start-up businesses in 178 countries. In this edition of Yer Biotech Blues, he notes that the United States and other major developed nations rank lower...

Globalization briskly marches on - one step ahead of our ability to measure and understand its effects. Economists, corporate leaders, and government officials trumpet the benefits of globalization but few have called attention to the risks for countries, companies, and individuals, opines Tony DiRomualdo. ...

Global companies are discovering Wisconsin's many business benefits, as Microsoft's recent acquisition of Jellyfish.com clearly demonstrates, according to Inside Wisconsin columnist Tom Still. Microsoft, however, is only the latest corporate giant to "Discover Wisconsin" and its business merits, which speaks volumes about Wisconsin's ability...

WiMAX will be a big alternative to big cities, especially after the “free” Wi-Fi business model has fizzled, observes James Carlini, and that's one of several impressions from the recent WiMAX WORLD Conference in Chicago. In this edition of Carlini's Comments, he said the conference...

Cellectar, which designs and develops products to detect, treat, and monitor human cancers, has named Ernest Allen as director of clinical operations and Lisa Ann Trembath as manager of medical affairs. The appointments come as Cellectar moves its lead drug candidate toward clinical trials....